The safety of our clinical trial participants, their families and carers, our employees, and the entire rare disease community is our top priority. At Lysogene we are actively and continuously working with our clinical trial sites, regulatory authorities and ethics committees to assess potential impacts and reduce families’ potential exposure to COVID-19, whilst continuing to provide medically necessary study care. If you have any concerns or questions, please contact your study doctor.